8-K
Turning Point Brands, Inc. (TPB)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): **** May 7, 2025
TURNING POINT BRANDS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-37763 | 20-0709285 |
|---|---|---|
| (State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 5201 Interchange Way, Louisville, KY | 40229 | |
| --- | --- | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (502) 778-4421
| N/A |
|---|
(Former name, former address and former fiscal year, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, $0.01 par value | TPB | New York Stock Exchange |
Check the appropriate box below if the Form 8–K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02. | Results of Operations and Financial Condition. |
|---|
On May 7, 2025, Turning Point Brands, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Such information will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference.
| Item 7.01. | Regulation FD Disclosure. |
|---|
On May 7, 2025, the Company posted an investor presentation with supplemental information for the quarter ended March 31, 2025 to the investor relations section of its website at the following link https://www.turningpointbrands.com/investor-relations/events-and-presentations.
The information furnished under Item 7.01 of this Current Report on Form 8-K, including the referenced investor presentation, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
| Item 9.01. | Financial Statements and Exhibits. |
|---|---|
| (d) | Exhibits |
| --- | --- |
| 99.1 | Press Release dated May 7, 2025 |
| --- | --- |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| --- | --- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TURNING POINT BRANDS, INC. | ||
|---|---|---|
| Dated: May 7, 2025 | By: | /s/ Brittani N. Cushman |
| Brittani N. Cushman | ||
| Senior Vice President, General Counsel and Secretary |
ex_813015.htm
Exhibit 99.1
Turning Point Brands Announces First Quarter 2025 Results
| ● | Net Sales for Q1 2025 Increased 28.1% Year-Over-Year to $106.4 million |
|---|---|
| ● | Modern Oral Net Sales for Q1 2025 of $22.3 million |
| --- | --- |
| ● | Q1 2025 Adjusted EBITDA of $27.7 million, up 12.0% over prior year |
| --- | --- |
| ● | Reaffirm our previously announced 2025 Adjusted EBITDA guidance of $108.0 –113.0 million; increasing full-year consolidated nicotine pouch sales guidance to a range of $80.0 –95.0 million, from $60.0 –80.0 million |
| --- | --- |
LOUISVILLE, KY – May 7, 2025 – Turning Point Brands, Inc. (“TPB” or “the Company”) (NYSE: TPB), a manufacturer, marketer and distributor of branded consumer products, including alternative smoking accessories and consumables with active ingredients, today announced financial results for the first quarter ended March 31, 2025.
Q1 2025 vs. Q1 2024
| ● | Total consolidated net sales increased 28.1% to $106.4 million |
|---|---|
| o | Stoker’s Products net sales increased 62.7% |
| --- | --- |
| o | Zig-Zag Products net sales increased 1.2% |
| --- | --- |
| ● | Gross profit increased 23.3% to $59.6 million |
| --- | --- |
| ● | Net income increased 19.8% to $14.4 million |
| --- | --- |
| ● | Adjusted EBITDA increased 12.0% to $27.7 million (see Schedule A for a reconciliation to net income) |
| --- | --- |
| ● | Adjusted net income increased 8.0% to $16.7 million (see Schedule B for a reconciliation to net income) |
| --- | --- |
| ● | Diluted EPS of $0.79 and Adjusted Diluted EPS of $0.91 compared to $0.63 and $0.80, respectively, in the same period one year ago (see Schedule B for a reconciliation to Diluted EPS) |
| --- | --- |
Graham Purdy, President and CEO, commented, “We are pleased with our first quarter results. Modern Oral sales were $22.3 million, up nearly 10-times versus the prior year and nearly double the prior quarter. Stoker’s MST and looseleaf exceeded our expectations, and Zig-Zag was in line with our expectations.”
Zig-Zag Products Segment (44% of total net sales in the quarter)
For the first quarter, Zig-Zag Products net sales increased 1.2% to $47.3 million.
For the quarter, the Zig-Zag Products segment gross profit decreased 7.2% from the prior year but was up 2.9% sequentially from Q4 2024 to $25.6 million. Gross margin declined 490 basis points from the prior year but was flat sequentially at 54.1%.
Stoker’s Products Segment (56% of total net sales in the quarter)
For the first quarter, Stoker’s Products net sales increased 62.7% to $59.2 million, driven by strong growth in Modern Oral sales, low double-digit growth in MST and low single-digit growth in looseleaf. For the first quarter, total Stoker’s Products segment volume increased 55.1%, while price / product mix increased 7.6%.
For the quarter, Stoker’s Products segment gross profit increased 63.6% from the prior year, and 23.5% sequentially from Q4 2024 to $34.0 million. Gross margin increased 30 basis points from the prior year, but decreased 20 basis points sequentially to 57.5%.
Performance Measures in the First Quarter
First quarter 2025 consolidated selling, general and administrative (“SG&A”) expenses were $36.4 million compared to $29.1 million in the first quarter of 2024 primarily driven by ALP-related SG&A that was not in the prior year period.
First quarter SG&A included the following notable items:
| ● | $1.6 million of FDA PMTA-related expenses for modern oral products compared to $0.8 million in the prior year period; and |
|---|---|
| ● | $0.2 million of transaction-related costs compared to $0.0 million in the prior year period. |
| --- | --- |
Total gross debt as of March 31, 2025 was $300.0 million. Net debt (total gross debt less unrestricted cash) as of March 31, 2025 was $200.4 million. The Company ended the quarter with total liquidity of $161.8 million, comprised of $99.6 million in cash and $62.2 million of availability under its asset backed revolving credit facility.
2025 Outlook
The Company is increasing projected Modern Oral sales from $60.0 – 80.0 million to $80.0 – 95.0 million.
The Company is maintaining its previous expectation for full-year 2025 adjusted EBITDA of $108.0 – 113.0 million.
Earnings Conference Call
As previously disclosed, a conference call with the investment community to review TPB’s financial results has been scheduled for 9:30 a.m. Eastern on Wednesday, May 7, 2025. Investment community participants should dial in 10 minutes ahead of time using the toll-free number (800) 715-9871 (international participants should call (646) 307-1963) and follow the audio prompts after typing in the event ID: 6640134. A live listen-only webcast of the call will be available on the Events and Presentations section of the investor relations portion of the Company website (www.turningpointbrands.com). A replay of the webcast will be available on the site two hours following the call.
2
Turning Point Brands, Inc. | www.turningpointbrands.com | ir@tpbi.com | 502.774.9238
Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally accepted accounting principles in the United States (GAAP), this press release includes certain non-GAAP financial measures including EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS and Adjusted Operating Income (Loss). A reconciliation of these non-GAAP financial measures accompanies this release. ****
About Turning Point Brands, Inc.
Turning Point Brands (NYSE: TPB) is a manufacturer, marketer and distributor of branded consumer products including smoking accessories and consumables with active ingredients through its Zig-Zag®, Stoker’s®, FRE ®, and Alp Pouch ® brands. TPB’s products are available in more than 220,000 retail outlets in North America, and on sites such as www.zigzag.com. For the latest news and information about TPB and its brands, please visit www.turningpointbrands.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may generally be identified by the use of words such as "anticipate," "believe," "expect," "intend," "plan" and "will" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. As a result, these statements are not guarantees of future performance and actual events may differ materially from those expressed in or suggested by the forward-looking statements. Any forward-looking statement made by TPB in this press release, its reports filed with the Securities and Exchange Commission (the “SEC”) and other public statements made from time-to-time speak only as of the date made. New risks and uncertainties come up from time to time, and it is impossible for TPB to predict or identify all such events or how they may affect it. TPB has no obligation, and does not intend, to update any forward-looking statements after the date hereof, except as required by federal securities laws. Factors that could cause these differences include, but are not limited to, those included in the Company’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed by the Company with the SEC. These statements constitute the Company’s cautionary statements under the Private Securities Litigation Reform Act of 1995.
Investor Contacts
Turning Point Brands, Inc.
ir@tpbi.com
Financial Statements Follow on Subsequent Pages
3
Turning Point Brands, Inc. | www.turningpointbrands.com | ir@tpbi.com | 502.774.9238
| Turning Point Brands, Inc. | ||||||
|---|---|---|---|---|---|---|
| Consolidated Statements of Income | ||||||
| (dollars in thousands except share data) | ||||||
| (unaudited) | ||||||
| Three Months Ended March 31, | ||||||
| --- | --- | --- | --- | --- | --- | --- |
| 2025 | 2024 | |||||
| Net sales | $ | 106,436 | $ | 83,064 | ||
| Cost of sales | 46,826 | 34,710 | ||||
| Gross profit | 59,610 | 48,354 | ||||
| Selling, general, and administrative expenses | 36,421 | 29,084 | ||||
| Operating income | 23,189 | 19,270 | ||||
| Interest expense, net | 4,414 | 3,479 | ||||
| Investment gain | (291 | ) | (119 | ) | ||
| Loss on extinguishment of debt | 1,235 | - | ||||
| Income from continuing operations before income taxes | 17,831 | 15,910 | ||||
| Income tax expense | 2,040 | 3,729 | ||||
| Income from continuing operations | 15,791 | 12,181 | ||||
| Loss from discontinued operations, net of tax | - | (2 | ) | |||
| Consolidated net income | 15,791 | 12,179 | ||||
| Net income attributable to non-controlling interest | 1,396 | 169 | ||||
| Net income attributable to Turning Point Brands, Inc. | $ | 14,395 | $ | 12,010 | ||
| Basic income per common share: | ||||||
| Continuing operations | $ | 0.81 | $ | 0.68 | ||
| Discontinued operations | - | - | ||||
| Net income attributable to Turning Point Brands, Inc. | $ | 0.81 | $ | 0.68 | ||
| Diluted income per common share: | ||||||
| Continuing operations | $ | 0.79 | $ | 0.63 | ||
| Discontinued operations | - | - | ||||
| Net income attributable to Turning Point Brands, Inc. | $ | 0.79 | $ | 0.63 | ||
| Weighted average common shares outstanding: | ||||||
| Basic | 17,795,243 | 17,654,684 | ||||
| Diluted | 18,249,306 | 20,170,314 |
4
Turning Point Brands, Inc. | www.turningpointbrands.com | ir@tpbi.com | 502.774.9238
| Turning Point Brands, Inc. | |||||
|---|---|---|---|---|---|
| Consolidated Balance Sheets | |||||
| (dollars in thousands except share data) | |||||
| **** | **** | **** | |||
| --- | --- | --- | --- | --- | --- |
| December 31, | |||||
| 2024 | |||||
| ASSETS | **** | **** | **** | **** | **** |
| Current assets: | |||||
| Cash | 99,640 | $ | 46,158 | ||
| Accounts receivable, net of allowances of 75 in 2025 and 66 in 2024 | 14,861 | 9,624 | |||
| Inventories, net | 104,440 | 96,253 | |||
| Current assets held for sale | - | 11,470 | |||
| Other current assets | 40,072 | 34,700 | |||
| Total current assets | 259,013 | 198,205 | |||
| Property, plant, and equipment, net | 27,659 | 26,337 | |||
| Deferred tax assets, net | - | 995 | |||
| Right of use assets | 10,788 | 11,610 | |||
| Deferred financing costs, net | 1,662 | 1,823 | |||
| Goodwill | 135,780 | 135,932 | |||
| Other intangible assets, net | 64,939 | 65,254 | |||
| Master Settlement Agreement (MSA) escrow deposits | 29,317 | 28,676 | |||
| Noncurrent assets held for sale | - | 3,859 | |||
| Other assets | 35,394 | 20,662 | |||
| Total assets | 564,552 | $ | 493,353 | ||
| LIABILITIES AND STOCKHOLDERS' EQUITY | **** | **** | **** | **** | **** |
| Current liabilities: | |||||
| Accounts payable | 27,007 | $ | 11,675 | ||
| Accrued liabilities | 31,596 | 31,096 | |||
| Current liabilities held for sale | - | 2,049 | |||
| Total current liabilities | 58,603 | 44,820 | |||
| Deferred tax liabilities, net | 885 | - | |||
| Notes payable and long-term debt | 293,062 | 248,604 | |||
| Lease liabilities | 8,565 | 9,549 | |||
| Total liabilities | 361,115 | $ | 302,973 | ||
| Commitments and contingencies | |||||
| Stockholders' equity: | |||||
| Preferred stock, 0.01 par value; authorized shares 40,000,000; issued and outstanding shares -0- | - | - | |||
| Common stock, voting, 0.01 par value; authorized shares, 190,000,000; 20,366,910 issued shares and 17,895,505 outstanding shares at March 31, 2025, and 20,200,886 issued shares and 17,729,481 outstanding shares at December 31, 2024 | 204 | 202 | |||
| Common stock, nonvoting, 0.01 par value; authorized shares, 10,000,000; issued and outstanding shares -0- | - | - | |||
| Additional paid-in capital | 124,811 | 126,662 | |||
| Cost of repurchased common stock (2,471,405 shares at March 31, 2025 and December 31, 2024) | (83,144 | ) | (83,144 | ) | |
| Accumulated other comprehensive loss | (2,363 | ) | (2,903 | ) | |
| Accumulated earnings | 160,182 | 147,164 | |||
| Non-controlling interest | 3,747 | 2,399 | |||
| Total stockholders' equity | 203,437 | 190,380 | |||
| Total liabilities and stockholders' equity | 564,552 | $ | 493,353 |
All values are in US Dollars.
5
Turning Point Brands, Inc. | www.turningpointbrands.com | ir@tpbi.com | 502.774.9238
| Turning Point Brands, Inc. | ||||||
|---|---|---|---|---|---|---|
| Consolidated Statements of Cash Flows | ||||||
| (dollars in thousands) | ||||||
| (unaudited) | ||||||
| Three Months Ended March 31, | ||||||
| --- | --- | --- | --- | --- | --- | --- |
| 2025 | 2024 | |||||
| Cash flows from operating activities: | ||||||
| Consolidated net income | $ | 15,791 | $ | 12,179 | ||
| Loss from discontinued operations, net of tax | - | 2 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||
| Loss on extinguishment of debt | 1,235 | - | ||||
| Loss on sale of property, plant, and equipment | 40 | 1 | ||||
| Depreciation and other amortization expense | 1,309 | 848 | ||||
| Amortization of other intangible assets | 307 | 305 | ||||
| Amortization of deferred financing costs | 448 | 696 | ||||
| Deferred income tax expense | 1,716 | 114 | ||||
| Stock compensation expense | 1,664 | 2,062 | ||||
| Noncash lease income | (380 | ) | (42 | ) | ||
| Loss on MSA investments | - | 6 | ||||
| Changes in operating assets and liabilities: | ||||||
| Accounts receivable | (5,539 | ) | 1,846 | |||
| Inventories | (8,310 | ) | (7,488 | ) | ||
| Other current assets | (5,399 | ) | 1,050 | |||
| Other assets | (4,201 | ) | (270 | ) | ||
| Accounts payable | 15,433 | 10,800 | ||||
| Accrued liabilities and other | 512 | (2,933 | ) | |||
| Operating cash flows from continuing operations | 14,626 | 19,176 | ||||
| Operating cash flows from discontinued operations | - | 3,463 | ||||
| Net cash provided by operating activities | $ | 14,626 | $ | 22,639 | ||
| Cash flows from investing activities: | ||||||
| Capital expenditures | $ | (2,185 | ) | $ | (366 | ) |
| Purchases of investments | (714 | ) | (7,119 | ) | ||
| Proceeds from sale of investments | 500 | - | ||||
| Purchases of non-marketable equity investments | - | (500 | ) | |||
| MSA escrow deposits, net | (48 | ) | (1 | ) | ||
| Investing cash flows from continuing operations | (2,447 | ) | (7,986 | ) | ||
| Investing cash flows from discontinued operations | - | - | ||||
| Net cash used in investing activities | $ | (2,447 | ) | $ | (7,986 | ) |
| Cash flows from financing activities: | ||||||
| Redemption of 2026 Notes | $ | (250,000 | ) | $ | - | |
| Proceeds from 2032 Notes | 300,000 | - | ||||
| Payment of dividends | (1,385 | ) | (1,149 | ) | ||
| Payment of financing costs | (6,582 | ) | - | |||
| Exercise of options | 973 | 3 | ||||
| Redemption of options | (33 | ) | - | |||
| Redemption of restricted stock units | (1,828 | ) | (136 | ) | ||
| Redemption of performance based restricted stock units | (2,625 | ) | (1,212 | ) | ||
| Common stock repurchased | - | (2,079 | ) | |||
| Financing cash flows from continuing operations | 38,520 | (4,573 | ) | |||
| Financing cash flows from discontinued operations | - | - | ||||
| Net cash provided by (used in) financing activities | $ | 38,520 | $ | (4,573 | ) | |
| Net increase in cash | $ | 50,699 | $ | 10,080 | ||
| Effect of foreign currency translation on cash | $ | (48 | ) | $ | (58 | ) |
| Cash, beginning of period: | ||||||
| Unrestricted | $ | 48,941 | $ | 117,886 | ||
| Restricted | 1,961 | 4,929 | ||||
| Total cash at beginning of period | $ | 50,902 | $ | 122,815 | ||
| Cash, end of period: | ||||||
| Unrestricted | $ | 99,640 | $ | 130,903 | ||
| Restricted | 1,913 | 1,934 | ||||
| Total cash at end of period | $ | 101,553 | $ | 132,837 |
6
Turning Point Brands, Inc. | www.turningpointbrands.com | ir@tpbi.com | 502.774.9238
Non-GAAP Financial Measures
To supplement our financial information presented in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, we use non-U.S. GAAP financial measures, including EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS, and Adjusted Operating Income . We believe Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to our financial condition and results of operations. Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS, and Adjusted Operating Income are used by management to compare our performance to that of prior periods for trend analyses and planning purposes and are presented to our board of directors. We believe that EBITDA, Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted EPS, and Adjusted Operating Income are appropriate measures of operating performance because they eliminate the impact of expenses that do not relate to business performance.
We define “EBITDA” as net income before interest expense, gain (loss) on extinguishment of debt, income tax expense, depreciation, amortization. We define “Adjusted EBITDA” as net income before interest expense, gain (loss) on extinguishment of debt, income tax expense, depreciation, amortization, other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Net Income” as net income excluding items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Diluted EPS” as diluted earnings per share excluding items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Operating Income” as operating income excluding other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance.
Non-U.S. GAAP measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. EBITDA, Adjusted Net Income, Adjusted EBITDA, Adjusted Diluted EPS, and Adjusted Operating Income exclude significant expenses that are required by U.S. GAAP to be recorded in our financial statements and is subject to inherent limitations. In addition, other companies in our industry may calculate this non-U.S. GAAP measure differently than we do or may not calculate it at all, limiting its usefulness as a comparative measure.
In accordance with SEC rules, we have provided, in the supplemental information attached, a reconciliation of the non-GAAP measures to the next directly comparable GAAP measures.
7
Turning Point Brands, Inc. | www.turningpointbrands.com | ir@tpbi.com | 502.774.9238
| Schedule A | ||||
|---|---|---|---|---|
| Turning Point Brands, Inc. | ||||
| Reconciliation of GAAP Net Income to Adjusted EBITDA | ||||
| (dollars in thousands) | ||||
| (unaudited) | ||||
| Three Months Ended | ||||
| --- | --- | --- | --- | --- |
| March 31, | ||||
| 2025 | 2024 | |||
| Net income attributable to Turning Point Brands, Inc. | $ | 14,395 | $ | 12,010 |
| Add: | ||||
| Interest expense, net | 4,401 | 3,479 | ||
| Loss on extinguishment of debt | 1,235 | - | ||
| Income tax expense | 2,040 | 3,729 | ||
| Depreciation expense | 828 | 741 | ||
| Amortization expense | 822 | 412 | ||
| EBITDA | $ | 23,721 | $ | 20,371 |
| Components of Adjusted EBITDA | ||||
| Corporate restructuring (a) | - | 1,261 | ||
| ERP/CRM (b) | 211 | 138 | ||
| Stock based compensation (c) | 1,664 | 2,062 | ||
| Transactional expenses and strategic initiatives (d) | 176 | 30 | ||
| FDA PMTA (e) | 1,591 | 841 | ||
| Mark-to-market loss on Canadian inter-company note (f) | 315 | - | ||
| Adjusted EBITDA | $ | 27,678 | $ | 24,703 |
| (a) | Represents costs associated with corporate restructuring, including severance and early retirement. | |||
| --- | --- | |||
| (b) | Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses. | |||
| (c) | Represents non-cash stock options, restricted stock, PRSUs, etc. | |||
| (d) | Represents the fees incurred for transaction expenses. | |||
| (e) | Represents costs associated with applications related to FDA premarket tobacco product application (“PMTA”). The PMTA regime requires the Company to submit an application to the FDA to receive marketing authorization to continue to sell certain of its product lines with continued sales permitted during the pendency of the applications. The application is a onetime resource-intensive process for each covered product line; however, due to the nature of the implementation process for those product lines already in the market, applications can take multiple years to complete rather than the typical one-time submission. The Company currently has only two product lines currently subject to the PMTA process, having utilized other regulatory pathway options available for our other product lines. The Company does not expect to submit additional PMTA applications for any new product lines after the submission for the remaining two are complete. | |||
| (f) | Represents a mark-to-market loss attributable to foreign exchange fluctuation. |
8
Turning Point Brands, Inc. | www.turningpointbrands.com | ir@tpbi.com | 502.774.9238
| Schedule B | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turning Point Brands | ||||||||||||||||||||||||||
| Reconciliation of GAAP Net Income to Adjusted Net Income and Diluted EPS to Adjusted Diluted EPS | ||||||||||||||||||||||||||
| (dollars in thousands except share data) | ||||||||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||||||
| Three Months Ended | Three Months Ended | |||||||||||||||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 31, 2025 | March 31, 2024 | |||||||||||||||||||||||||
| Income from continuing operations before income taxes | Income tax expense^(i)^ | Net income attributable to non-controlling interest | Net Income | Diluted EPS | Income from continuing operations before income taxes | Income tax expense^(i)^ | Loss from discontinued operations, net of tax ^(j)^ | Net income attributable to non-controlling interest | Net Income | Diluted EPS | ||||||||||||||||
| GAAP Net Income and Diluted EPS | $ | 17,831 | $ | 2,040 | $ | 1,396 | $ | 14,395 | $ | 0.79 | $ | 15,910 | $ | 3,729 | $ | 2 | $ | 169 | $ | 12,010 | $ | 0.63 | ||||
| Loss on discontinued operations (a) | - | - | - | - | - | - | - | (3 | ) | - | 3 | 0.00 | ||||||||||||||
| Loss on extinguishment of debt (b) | 1,235 | 141 | - | 1,094 | 0.06 | - | - | - | - | - | - | |||||||||||||||
| Corporate restructuring (c) | - | - | - | - | - | 1,261 | 295 | - | - | 966 | 0.05 | |||||||||||||||
| ERP/CRM (d) | 211 | 24 | - | 187 | 0.01 | 138 | 32 | - | - | 106 | 0.01 | |||||||||||||||
| Stock options, restricted stock, and incentives expense (e) | 1,664 | 190 | - | 1,474 | 0.08 | 2,062 | 483 | - | - | 1,579 | 0.08 | |||||||||||||||
| Transactional expenses and strategic initiatives (f) | 176 | 20 | - | 156 | 0.01 | 30 | 7 | - | - | 23 | 0.00 | |||||||||||||||
| FDA PMTA (g) | 1,591 | 182 | - | 1,409 | 0.08 | 841 | 197 | - | - | 644 | 0.03 | |||||||||||||||
| Mark-to-market loss on Canadian inter-company note (h) | 315 | 36 | - | 279 | 0.02 | - | - | |||||||||||||||||||
| Tax benefit (i) | - | 2,329 | - | (2,329 | ) | (0.13 | ) | - | (93 | ) | - | - | 93 | 0.00 | ||||||||||||
| Adjusted Net Income and Adjusted Diluted EPS | $ | 23,023 | $ | 4,963 | $ | 1,396 | $ | 16,664 | $ | 0.91 | $ | 20,242 | $ | 4,650 | $ | (1 | ) | $ | 169 | $ | 15,424 | $ | 0.80 | |||
| Totals may not foot due to rounding | ||||||||||||||||||||||||||
| --- | --- | |||||||||||||||||||||||||
| (a) | Represents loss on discontinued operations. | |||||||||||||||||||||||||
| (b) | Represents loss on extinguishment of debt as a result of the redemption of the 2026 Notes. | |||||||||||||||||||||||||
| (c) | Represents costs associated with corporate restructuring, including severance and early retirement. | |||||||||||||||||||||||||
| (d) | Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses. | |||||||||||||||||||||||||
| (e) | Represents non-cash stock options, restricted stock, PRSUs, etc. | |||||||||||||||||||||||||
| (f) | Represents the fees incurred for transaction expenses. | |||||||||||||||||||||||||
| (g) | Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA"). The PMTA regime requires the Company to submit an application to the FDA to receive marketing authorization to continue to sell certain of its product lines with continued sales permitted during the pendency of the applications. The application is a onetime resource-intensive process for each covered product line; however, due to the nature of the implementation process for those product lines already in the market, applications can take multiple years to complete rather than the typical one-time submission. The Company currently has only two product lines currently subject to the PMTA process, having utilized other regulatory pathway options available for our other product lines. The Company does not expect to submit additional PMTA applications for any new product lines after the submission for the remaining two are complete. | |||||||||||||||||||||||||
| (h) | Represents adjustment from quarterly tax rate to quarterly projected tax rate of 21% in 2025 and 23% in 2024. | |||||||||||||||||||||||||
| (i) | Income tax expense calculated using the effective tax rate for the quarter of 11.4% in 2025 and 23.4% in 2024. | |||||||||||||||||||||||||
| (j) | Tax allocation for discontinued operations excluded from adjusted net income. |
9
Turning Point Brands, Inc. | www.turningpointbrands.com | ir@tpbi.com | 502.774.9238
| Schedule C | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turning Point Brands, Inc. | ||||||||||||
| Reconciliation of GAAP Operating Income to Adjusted Operating Income | ||||||||||||
| (dollars in thousands) | ||||||||||||
| (unaudited) | ||||||||||||
| Consolidated | Zig-Zag Products | Stoker's Products | ||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1st Quarter | 1st Quarter | 1st Quarter | 1st Quarter | 1st Quarter | 1st Quarter | |||||||
| 2025 | 2024 | 2025 | 2024 | 2025 | 2024 | |||||||
| Net sales | $ | 106,436 | $ | 83,064 | $ | 47,265 | $ | 46,697 | $ | 59,171 | $ | 36,367 |
| Gross profit | $ | 59,610 | $ | 48,354 | $ | 25,565 | $ | 27,539 | $ | 34,045 | $ | 20,815 |
| Operating income | $ | 23,189 | $ | 19,270 | $ | 16,930 | $ | 18,000 | $ | 24,134 | $ | 15,396 |
| Adjustments: | ||||||||||||
| Corporate restructuring | - | 1,261 | - | - | - | - | ||||||
| ERP/CRM | 211 | 138 | - | - | - | - | ||||||
| Transactional expenses and strategic initiatives | 176 | 30 | - | - | - | - | ||||||
| FDA PMTA | 1,591 | 841 | - | - | - | - | ||||||
| Mark-to-market loss on Canadian inter-company note | 315 | - | - | - | - | - | ||||||
| Adjusted operating income | $ | 25,482 | $ | 21,540 | $ | 16,930 | $ | 18,000 | $ | 24,134 | $ | 15,396 |
10
Turning Point Brands, Inc. | www.turningpointbrands.com | ir@tpbi.com | 502.774.9238